Form 4 records show purchases on two dates
Electra Therapeutics related owners reported purchases of 42,700 shares of ETRA for $356,615 across November 9 and November 10. The transactions appear in Form 4 records filed on November 11. Those records name Carl L. Gordon and OrbiMed Advisors LLC as reporting persons, and each party's entries repeat the same underlying purchase details. Counting each matching transaction once avoids treating the duplicated disclosure as two separate sets of shares.
The trade rows identify both reporters as directors and as owners of more than 10 percent. They classify the activity as non-derivative purchases of common stock, with code P and shares acquired. The reported prices were $8.24 for the November 9 purchases and $8.45 for the November 10 purchases. These are reported transaction prices, not a claim about the value of the shares at another point in time.
The two dated filing records provide a focused account of the activity. The entries describe purchases through an indirect ownership relationship, rather than a simple record of an individual executive acquiring shares directly. The distinction matters when several names appear against matching trades. More filing details and the ticker page are available on SecBot's ETRA stock page and insider tracker.
The transaction arithmetic
The underlying entries show four purchase amounts across the two dates. On November 9, one purchase row records 16,000 shares at $8.24, valued at $131,840. Another records 4,000 shares at the same price, valued at $32,960. Together, those two unique rows account for 20,000 shares. On November 10, the records show a 20,700-share purchase at $8.45 for $174,915, plus a 2,000-share purchase at that price for $16,900.
| Transaction date | Shares | Price per share | Reported value |
|---|---|---|---|
| November 9 | 16,000 | $8.24 | $131,840 |
| November 9 | 4,000 | $8.24 | $32,960 |
| November 10 | 20,700 | $8.45 | $174,915 |
| November 10 | 2,000 | $8.45 | $16,900 |
Across the four unique purchase rows, the combined total is 42,700 shares and $356,615. The implied average price, calculated from the combined value divided by the combined shares, is $8.35 per share when rounded to cents. That average summarizes the listed transaction values; it does not mean every share was bought at the same price. The two transaction prices were different, and the disclosed share amounts were also different.
Why the records repeat
SecBot's Form 4 trade data has matching entries filed under Gordon and OrbiMed Advisors. For each of the two November 10 purchases, both reporting names show 20,700 shares at $8.45 and 2,000 shares at $8.45. For November 9, each name likewise has matching 16,000-share and 4,000-share entries at $8.24. Their reported holdings after each purchase match as well. These repeated fields are the basis for counting the activity as two transaction amounts per date, not four amounts per date.
The filing footnote identifies OrbiMed Private Investments VII, LP as the direct holder of the securities. It describes OrbiMed Capital GP VII LLC as the fund's general partner and OrbiMed Advisors LLC as the managing member of that general partner. The filing data therefore associates the holdings with an indirect ownership chain. Gordon is separately named as a reporting person. This is why the disclosure can show the same positions under more than one reporting name without establishing that twice as many shares changed hands.
The record lists post-transaction holdings of 2,194,579 shares for one reported position and 5,255,278 shares for another after the November 10 entries. The corresponding November 9 rows show holdings after those earlier purchases of 2,192,579 shares and 5,234,578 shares. These are filing-reported position figures, not a statement that all shares are held in one personal account. The two holdings should not be added to the purchase total, because they represent holdings after the reported transactions rather than newly acquired shares.
Price context from the same period
The stored daily price history shows ETRA closed at $8.22 on November 9 and $7.99 on November 10. Those closes give context around the transaction dates, but they do not determine the terms of the purchases. The November 9 close was below the reported $8.24 transaction price, while the November 10 close was below the $8.45 transaction price. A daily close and an insider's weighted transaction price can reflect different trades and different times within the session.
The historical data also records trading volume of 428,300 shares on November 9 and 298,200 shares on November 10. Those figures describe total reported daily volume, not a measure of who was on the other side of the reported purchases. The Form 4 rows do not establish whether the purchases affected the closing price, nor do they show the identity of counterparties. The close and volume observations are best read as limited market context alongside the specific ownership disclosures.
A separate filing result for ETRA reports a Schedule 13G filed on October 29. Its local analysis describes Westlake BioPartners entities and Dr. Beth C. Seidenberg as reporting a combined beneficial ownership position of 10.1 percent. This is a separate ownership disclosure from the November Form 4 purchases. The datasets do not say that the two sets of filings are connected, so the 13G is context about another reported owner, not an explanation for the purchases discussed here.
What the disclosures do not say
A Form 4 reports the transaction details and the ownership relationship represented in the filing. It does not provide a reason for a purchase. These entries do not state whether the transactions were made in response to company news, reflect a view about future performance, or form part of a broader plan. The rows also do not establish that the named reporting persons coordinated their actions, beyond the relationship that the footnote explicitly describes.
The data is limited to locally available records. It does not provide a complete account of all beneficial ownership or every transaction in ETRA shares. It does not establish how long any position will be held. The duplicate reporting entries require care, and the totals here count repeated disclosures only once when the date, quantity, price, and post-transaction position match. The arithmetic is confined to those unique purchase rows.
SecBot's SEC filings page provides another route to filing records, while the ticker and insider pages present company-specific context. These pages do not change the limits of the reported data. The next concrete disclosure point available in these records is the November 11 filing date attached to the two Form 4 filings. For access to SecBot's broader research tools, register here.